Letter

Postmarketing surveillance does not catch all adverse events

BMJ 1996; 312 doi: 10.1136/bmj.312.7030.577 (Published 2 March 1996)
Cite this as: BMJ 1996;312:577.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Paul O'Brien
  1. Session clinical medical officer Raymede Clinic, London W10 5SH

    EDITOR,—H B M Reijnen and W J Atsma, of Organon Pharmaceuticals, use data from the company's product surveillance database to show that the risk of venous thromboembolism with the pills Marvelon and Mercilon, both of which contain desogestrel, is highest in the first few months of use and falls dramatically thereafter.1 The World Health Organisation's …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular